+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Citeline - Market Research Reports

Citeline's analysis, insight and consultancy services span drug, device, company, clinical trial and market intelligence. All services are delivered by an authoritative team of industry experts in key markets around the globe.

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened - As Have These Other Shocking Tales Of Irregular FDA Inspections - Product Thumbnail Image

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened - As Have These Other Shocking Tales Of Irregular FDA Inspections

  • Newsletter
  • September 2026
  • 5 Pages
  • Global
From
Accenture Prescribes A New Data Management Future For Medtechs - Product Thumbnail Image

Accenture Prescribes A New Data Management Future For Medtechs

  • Newsletter
  • September 2026
  • 5 Pages
  • Global
From
EMA To Re-Prioritize Tasks To Cope With 'Higher Than Expected' Staff Losses - Product Thumbnail Image

EMA To Re-Prioritize Tasks To Cope With 'Higher Than Expected' Staff Losses

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology - Product Thumbnail Image

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

  • Newsletter
  • September 2026
  • 4 Pages
  • Global
From
US FDA May Largely Avoid House Democrats' Investigation Agenda - Product Thumbnail Image

US FDA May Largely Avoid House Democrats' Investigation Agenda

  • Newsletter
  • September 2026
  • 3 Pages
  • United States
From
FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence - Product Thumbnail Image

FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
J&J Scores Early In 'Hypoallergenic' Case; Plaintiff's Definition 'Implausible,' Court Says - Product Thumbnail Image

J&J Scores Early In 'Hypoallergenic' Case; Plaintiff's Definition 'Implausible,' Court Says

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It - Product Thumbnail Image

What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Bayer's US Playbook: The Smart Way To Top-Line Growth - Product Thumbnail Image

Bayer's US Playbook: The Smart Way To Top-Line Growth

  • Newsletter
  • September 2026
  • 7 Pages
  • United States
From
Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits - Product Thumbnail Image

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

  • Newsletter
  • September 2026
  • 6 Pages
  • Global
From
What Should You Be Earning? Salary Benchmarks And Hiring Trends In Regulatory Affairs - Product Thumbnail Image

What Should You Be Earning? Salary Benchmarks And Hiring Trends In Regulatory Affairs

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Nail Polishes Contain Undeclared DEHP, Among Other 'Regrettable Substitutions' - Study - Product Thumbnail Image

Nail Polishes Contain Undeclared DEHP, Among Other 'Regrettable Substitutions' - Study

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
New Year Present For Takeda As Shire Close Nears? - Product Thumbnail Image

New Year Present For Takeda As Shire Close Nears?

  • Newsletter
  • September 2026
  • 4 Pages
  • Global
From
FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework - Product Thumbnail Image

FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars - Product Thumbnail Image

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Gene Therapy's Next Big Challenge: Manufacturing - Product Thumbnail Image

Gene Therapy's Next Big Challenge: Manufacturing

  • Newsletter
  • September 2026
  • 5 Pages
  • Global
From
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting - Product Thumbnail Image

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

  • Newsletter
  • September 2026
  • 4 Pages
  • Global
From
Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him - Product Thumbnail Image

Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
DECIEM, Truly 'The Abnormal Beauty Company,' Faces Uncertain Future - Product Thumbnail Image

DECIEM, Truly 'The Abnormal Beauty Company,' Faces Uncertain Future

  • Newsletter
  • September 2026
  • 3 Pages
  • Global
From
Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry - Product Thumbnail Image

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

  • Newsletter
  • September 2026
  • 2 Pages
  • Global
From
Loading Indicator